{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:39:28Z","timestamp":1768315168277,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,8,4]],"date-time":"2006-08-04T00:00:00Z","timestamp":1154649600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>In osteonecrosis the vascular supply of the bone is interrupted and the living cells die. The inorganic mineral network remains intact until ingrowing blood vessels invade the graft. Accompanying osteoclasts start to resorb the bone trabeculae and gradually replace the bone. If the osteonecrosis occurs in mechanically loaded parts, like in the subchondral bone of a loaded joint, the remodelling might lead to a weakening of the bone and, in consequence to a joint collapse. Systemic bisphosphonate treatment can reduce the resorption of necrotic bone. In the present study we investigate if zoledronate, the most potent of the commercially available bisphosphonates, can be used to reduce the amount or speed of bone graft remodeling.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Bone grafts were harvested and placed in a bone chamber inserted into the tibia of a rat. Host tissue could grow into the graft through openings in the chamber. Weekly injections with 1.05 \u03bcg zoledronate or saline were given subcutaneously until the rats were harvested after 6 weeks. The specimens were fixed, cut and stained with haematoxylin\/eosin and used for histologic and histomorphometric analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>By histology, the control specimens were almost totally resorbed in the remodeled area and the graft replaced by bone marrow. In the zoledronate treated specimens, both the old graft and new-formed bone remained and the graft trabeculas were lined with new bone. By histomorphometry, the total amount of bone (graft+ new bone) within the remodelled area was 35 % (SD 13) in the zoledronate treated grafts and 19 % (SD 12) in the controls (p = 0.001). Also the amount of new bone was increased in the treated specimens (22 %, SD 7) compared to the controls (14 %, SD 9, p = 0.032).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We show that zoledronate can be used to decrease the resorption of both old graft and new-formed bone during bone graft remodelling. This might be useful in bone grafting procedure but also in other orthopedic conditions, both where necrotic bone has to be remodelled i.e. after osteonecrosis of the knee and hip and in Perthes disease, or in high load, high turnover conditions like delayed union, periprosthetic osteolysis or bone lengthening operations. In our model an increased net formation of new bone was found which probably reflects that new bone formed was retained by the action of the bisphosphonates rather than a true anabolic effect.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2474-7-63","type":"journal-article","created":{"date-parts":[[2006,8,5]],"date-time":"2006-08-05T02:05:13Z","timestamp":1154743513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Systemic zoledronate treatment both prevents resorption of allograft bone and increases the retention of new formed bone during revascularization and remodelling. A bone chamber study in rats"],"prefix":"10.1186","volume":"7","author":[{"given":"J\u00f6rgen","family":"\u00c5strand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Kajsa","family":"Harding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Aspenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"T\u00e4gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,8,4]]},"reference":[{"key":"237_CR1","first-page":"273","volume-title":"Clin Orthop","author":"MJ Glimcher","year":"1979","unstructured":"Glimcher MJ, Kenzora JE: The biology of osteonecrosis of the human femoral head and its clinical implications. III. Discussion of the etiology and genesis of the pathological sequelae; commments on treatment. Clin Orthop. 1979, 273-312."},{"key":"237_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/sarh.2002.33724b","volume":"32","author":"Y Assouline-Dayan","year":"2002","unstructured":"Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME: Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002, 32: 94-124.","journal-title":"Semin Arthritis Rheum"},{"key":"237_CR3","first-page":"17","volume-title":"Clin Orthop","author":"NL Parks","year":"1997","unstructured":"Parks NL, Engh GA: Histology of nine structural bone grafts used in total knee arthroplasty. Clin Orthop. 1997, 17-23. 10.1097\/00003086-199712000-00004."},{"key":"237_CR4","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1359\/jbmr.2003.18.11.2016","volume":"18","author":"DG Little","year":"2003","unstructured":"Little DG, Peat RA, Mcevoy A, Williams PR, Smith EJ, Baldock PA: Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J Bone Miner Res. 2003, 18: 2016-22. 10.1359\/jbmr.2003.18.11.2016.","journal-title":"J Bone Miner Res"},{"key":"237_CR5","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1080\/00016470410004157","volume":"75","author":"M T\u00e4gil","year":"2004","unstructured":"T\u00e4gil M, Astrand J, Westman L, Aspenberg P: Alendronate prevents collapse in mechanically loaded osteochondral grafts: a bone chamber study in rats. Acta Orthop Scand. 2004, 75: 756-61. 10.1080\/00016470410004157.","journal-title":"Acta Orthop Scand"},{"key":"237_CR6","doi-asserted-by":"publisher","first-page":"550","DOI":"10.2106\/JBJS.D.02192","volume":"87","author":"HK Kim","year":"2005","unstructured":"Kim HK, Randall TS, Bian H, Jenkins J, Garces A, Bauss F: Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs. J Bone Joint Surg Am. 2005, 87: 550-7. 10.2106\/JBJS.D.02192.","journal-title":"J Bone Joint Surg Am"},{"key":"237_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00223-004-0024-1","volume":"75","author":"MJ Rogers","year":"2004","unstructured":"Rogers MJ: From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int. 2004, 75: 451-61. 10.1007\/s00223-004-0024-1.","journal-title":"Calcif Tissue Int"},{"key":"237_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/00006416-200511000-00003","volume":"24","author":"M McQuade","year":"2005","unstructured":"McQuade M, Houghton K: Use of bisphosphonates in a case of perthes disease. Orthop Nurs. 2005, 24: 393-8.","journal-title":"Orthop Nurs"},{"key":"237_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/01.blo.0000194078.32776.31","volume":"443","author":"T Nishii","year":"2006","unstructured":"Nishii T, Sugano N, Miki H, Hashimoto J, Yoshikawa H: Does alendronate prevent collapse in osteonecrosis of the femoral head?. Clin Orthop Relat Res. 2006, 443: 273-9. 10.1097\/01.blo.0000194078.32776.31.","journal-title":"Clin Orthop Relat Res"},{"key":"237_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/rheumatology\/keh481","volume":"44","author":"S Agarwala","year":"2005","unstructured":"Agarwala S, Jain D, Joshi VR, Sule A: Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology. 2005, 44: 352-9. 10.1093\/rheumatology\/keh481.","journal-title":"Rheumatology"},{"key":"237_CR11","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.2106\/JBJS.D.02959","volume":"87","author":"KA Lai","year":"2005","unstructured":"Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM: The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg. 2005, 87: 2155-9. 10.2106\/JBJS.D.02959.","journal-title":"J Bone Joint Surg"},{"key":"237_CR12","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1007\/s001250100008","volume":"44","author":"EB Jude","year":"2001","unstructured":"Jude EB, Selby PL, Burgess J, Lilleystone P, Mawer EB, Page SR, Donohoe M, Foster AV, Edmonds ME, Boulton AJ: Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia. 2001, 44: 2032-7. 10.1007\/s001250100008.","journal-title":"Diabetologia"},{"key":"237_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/000164700317362163","volume":"71","author":"M Hilding","year":"2000","unstructured":"Hilding M, Ryd L, Toksvig-Larsen S, Aspenberg P: Clodronate prevents prosthetic migration: a randomized radiostereometric study of 50 total knee patients. Acta Orthop Scand. 2000, 71: 553-7. 10.1080\/000164700317362163.","journal-title":"Acta Orthop Scand"},{"key":"237_CR14","first-page":"2126","volume-title":"J Bone Miner Res","author":"PK Venesmaa","year":"2001","unstructured":"Venesmaa PK, Kroger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhav EM: Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study. J Bone Miner Res. 2001, 2126-31. 10.1359\/jbmr.2001.16.11.2126."},{"key":"237_CR15","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1359\/JBMR.040709","volume":"19","author":"EJ Smith","year":"2004","unstructured":"Smith EJ, McEvoy A, Little DG, Baldock PA, Eisman JA, Gardiner EM: Transient retention of endochondral cartilaginous matrix with bisphosphonate treatment in a long-term rabbit model of distraction osteogenesis. J Bone Miner Res. 2004, 19: 1698-705. 10.1359\/JBMR.040709.","journal-title":"J Bone Miner Res"},{"key":"237_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/17453670610045650","volume":"77","author":"M T\u00e4gil","year":"2006","unstructured":"T\u00e4gil M, Aspenberg P, \u00c5strand J: Systemic zoledronate precoating of a bone graft reduces bone resorption during remodelling. Acta Orthop Scand. 2006, 77: 23-6.","journal-title":"Acta Orthop Scand"},{"key":"237_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1471-2474-3-19","volume":"3","author":"J \u00c5strand","year":"2002","unstructured":"\u00c5strand J, Aspenberg P: Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats. BMC Musculoskelet Disord. 2002, 3: 19-10.1186\/1471-2474-3-19.","journal-title":"BMC Musculoskelet Disord"},{"key":"237_CR18","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1517\/14656566.3.7.1007","volume":"7","author":"SA Doggrell","year":"2002","unstructured":"Doggrell SA: Zoledronate once-yearly increases bone mineral density--implications for osteoporosis. Expert Opin Pharmacother. 2002, 7: 1007-9. 10.1517\/14656566.3.7.1007. Review","journal-title":"Expert Opin Pharmacother"},{"key":"237_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/jor.1100140222","volume":"14","author":"JS Wang","year":"1996","unstructured":"Wang JS, Aspenberg P: Basic fibroblast growth factor enhances bone-graft incorporation: dose and time dependence in rats. J Orthop Res. 1996, 14: 316-23. 10.1002\/jor.1100140222.","journal-title":"J Orthop Res"},{"key":"237_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/BF00443391","volume":"114","author":"K Thoren","year":"1995","unstructured":"Thoren K, Aspenberg P: Increased bone ingrowth distance into lipid-extracted bank bone at 6 weeks. A titanium chamber study in allogeneic and syngeneic rats. Arch Orthop Trauma Surg. 1995, 114: 167-171. 10.1007\/BF00443391.","journal-title":"Arch Orthop Trauma Surg"},{"key":"237_CR21","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY: Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005, 90: 1294-301. 10.1210\/jc.2004-0952.","journal-title":"J Clin Endocrinol Metab"},{"key":"237_CR22","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA: Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004, 350: 1189-99. 10.1056\/NEJMoa030897.","journal-title":"N Engl J Med"},{"key":"237_CR23","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1016\/j.biomaterials.2003.11.024","volume":"18","author":"GI Im","year":"2004","unstructured":"Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS: Osteoblast proliferation and maturation by bisphosphonates. Biomaterials. 2004, 18: 4105-15. 10.1016\/j.biomaterials.2003.11.024.","journal-title":"Biomaterials"},{"key":"237_CR24","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1016\/j.biomaterials.2004.09.026","volume":"17","author":"C Wedemeyer","year":"2005","unstructured":"Wedemeyer C, von Knoch F, Pingsmann A, Hilken G, Sprecher C, Saxler G, Henschke F, Loer F, von Knoch M: Stimulation of bone formation by zoledronic acid in particle induced osteolysis. Biomaterials. 2005, 17: 3719-25. 10.1016\/j.biomaterials.2004.09.026.","journal-title":"Biomaterials"},{"key":"237_CR25","first-page":"6001","volume":"60","author":"GG Reinholz","year":"2000","unstructured":"Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC: Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 2000, 60: 6001-7.","journal-title":"Cancer Res"},{"key":"237_CR26","doi-asserted-by":"publisher","first-page":"7317","DOI":"10.1074\/jbc.M412817200","volume":"280","author":"LI Plotkin","year":"2005","unstructured":"Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T: Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem. 2005, 280: 7317-25. 10.1074\/jbc.M412817200.","journal-title":"J Biol Chem"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-7-63.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2474-7-63\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-7-63","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-7-63.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:37:15Z","timestamp":1630456635000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/1471-2474-7-63"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,4]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["237"],"URL":"https:\/\/doi.org\/10.1186\/1471-2474-7-63","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,4]]},"assertion":[{"value":"13 March 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"63"}}